# Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

> **NCT03341637** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 400 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** Tetravalent Dengue Vaccine (TDV)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03341637
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2019-01-26
- **Final completion:** 2019-01-26
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2019-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03341637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03341637, "Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03341637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*